ReviewCurrent pharmaceutical design2026
Cholangiocarcinoma in the Era of Precision Medicine: Emerging Insights and Therapeutic Strategies.
Review in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION/
objectiveCholangiocarcinoma is an aggressive malignancy of the biliary tract, with increasing global incidence and poor prognosis due to frequent late-stage diagnosis and nonspecific symptoms. It encompasses intrahepatic, perihilar, and distal subtypes, each with distinct clinical characteristics. This review outlines current and emerging therapeutic strategies for the treatment of resectable and advanced cholangiocarcinoma, with a focus on adjuvant therapies, systemic chemotherapy, immunotherapy, and targeted molecular approaches.
methodsA comprehensive literature search was conducted across major medical databases. Relevant randomized controlled trials, meta-analyses, clinical guidelines, and high-quality observational studies were reviewed. Emphasis was placed on recent evidence and emerging treatment modalities with clinical significance.
resultsCapecitabine remains the standard adjuvant chemotherapy regimen following resection, although optimal regimens are currently under investigation. Gemcitabine-cisplatin is the first-line chemotherapy regimen for advanced disease. Immunotherapy has shown benefit, especially in patients with microsatellite instability. Promising advances lie in targeted therapies, including fibroblast growth factor receptor inhibitors and isocitrate dehydrogenase 1 inhibitors, which have demonstrated improved outcomes in molecularly selected patients. DISCUSSION: The treatment landscape of cholangiocarcinoma continues to evolve. While chemotherapy remains foundational, increasing molecular characterization may offer improved disease control in selected subgroups.
conclusionAdvances in molecular profiling and immunotherapy are reshaping the management of cholangiocarcinoma, enabling more personalized treatment strategies. Continued integration of precision oncology into clinical practice and prospective trials will be critical to improving outcomes for cholangiocarcinoma moving forward.
Indexed as
Identifiers
42299004What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.